

id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
154602	18/SW/0121	239039	Feasibility of a family-based nutrition and physical activity intervention in young people with familial hypercholesterolaemia. A mixed methods study	Yes	06/03/2019	29	14	43	22/01/2019	22/01/2019	08/06/2018	20/02/2019	20/02/2019	Please Select...	06/03/2019			Please Select...
154603	18/YH/0127	239022	Instantaneous wave-free ratio guided multi-vessel revascularization during percutaneous coronary intervention for acute myocardial infarction	Yes	22/11/2019	82	185	267	28/02/2019	28/02/2019	21/05/2018	13/05/2019	21/05/2019	Please Select...	24/07/2019	A - Permissions delayed/denied E - Staff availability issues	Support department confirmation delayed. PI Annual leave	NHS Provider
154604	18/SC/0580	235355	FROSTTIE: A randomised controlled trial of Frenolomy and breastfeeding support Or breastfeeding Support without frenotomy to investigate continuation of breastfeeding for babies with Tongue-TIE	Yes	06/11/2019	36	169	205	06/02/2019	15/04/2019	19/12/2018	17/05/2019	21/05/2019	Please Select...	19/06/2019	G - No patients consented	Lots of patients screened, all declined or ineligible.	Neither
154605	18/LO/0071	229507	Adjuvant treatment for high-risk triple negative breast cancer patients with the anti-pd-1 antibody Avelumab: A phase III randomized trial	Yes	18/12/2019	23	147	170	12/04/2018	01/07/2019	03/04/2018	24/07/2019	24/07/2019	Please Select...	13/09/2019	D - Sponsor Delays F - No patients seen	Delays in receiving greenlight from sponsor. Low target for recruitment. No patients seen.	Sponsor
154606	17/NW/0634	209375	A randomized double blind placebo controlled Phase II clinical trial of Cediranib and Olaparib maintenance in advanced recurrent Cervical Cancer.	Yes	23/12/2019	64	81	145	13/06/2019	31/07/2019	16/01/2018	25/09/2019	03/10/2019	Please Select...	08/10/2019	D - Sponsor Delays F - No patients seen H - Contracting delays I - Rare diseases	Contract delays from sponsor. Rare disease.	Both
154607	18/EE/0095	239387	A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer	No		9			18/12/2018	16/09/2019	15/05/2018	19/09/2019	25/09/2019	Please Select...		D - Sponsor Delays	Permission given by site. No greenlight or correspondence received from Sponsor for several months following this.	Sponsor
154623	18/SC/0242	238151	A phase III randomised controlled trial of continuous beta lactam infusion compared with intermittent beta-lactam dosing in critically ill patients.	No					01/08/2019	22/10/2019	24/08/2018			Please Select...		H - Contracting delays	Contract delays	Both